Artiva Biotherapeutics reported positive initial clinical data for its AlloNK therapy in refractory rheumatoid arthritis (RA), showing a 71% ACR50 response rate in patients with six months follow-up. The treatment demonstrated good tolerability with no serious adverse events, supporting outpatient use in community settings. The FDA has aligned with Artiva on a Phase 3 registrational trial starting in the second half of 2026, comparing AlloNK plus rituximab against rituximab alone in about 150 refractory RA patients. This trial aims to address the significant unmet need in difficult-to-treat RA patients who have failed multiple prior therapies.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Hi-View Resources Inc. has started its 2026 exploration program in the Toodoggone Mining District, British Columbia, focusing on porphyry targets at key sites like Lawyer’s East, Borealis, and Golden Stranger. The program includes 50 line kilometres ...
The U.S. Patent and Trademark Office (USPTO) has introduced an AI-assisted image search feature in its public trademark search system, TM Search, using technology from Clarivate Plc. This new tool allows users to upload images and compare them agains...
AIB Data Centers Inc. is considered a speculative buy with a $3.50 price target based on its 65 MW energized capacity. The investment case depends heavily on securing a single anchor lease at its CLT-01 facility, which would validate its business mod...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
